- Primoris Services Corporation recently presented at the 2026 Cantor Global Technology & Industrial Growth Conference in New York, highlighting its role in building, maintaining, and upgrading utility, energy, and civil infrastructure.
- The presentation came as Primoris reported very large average backlog growth over the past two years, fast-compounding earnings, improved free cash flow margins, and stepped-up insider selling that has drawn closer scrutiny to management’s outlook and capital allocation.
- Against this backdrop of conference visibility and insider activity, we’ll assess how these developments intersect with Primoris’s data center and renewables-focused investment narrative.
The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Primoris Services Investment Narrative Recap
To own Primoris, you need to believe that its backlog, data center work, and renewables exposure can translate into durable earnings while it manages cyclicality in pipelines and utilities. The recent conference appearance and short-term share pullback on geopolitical worries do not materially change the near term catalyst, which is execution on its large backlog, or the key risk, which is winning enough higher quality data center and renewables work at acceptable margins.
The most relevant recent development here is Primoris’s Q4 2025 and full year 2025 results, which showed revenue of US$7,574.9 million and net income of US$274.9 million. Those figures, alongside 2026 EPS guidance of US$5.35 to US$5.55, frame how investors will judge any new color from management at the March conferences on data center opportunities, renewables timing, and whether insider selling signals caution or simply reflects portfolio decisions.
But even with backlog growth and higher earnings, investors should be aware of the risk that...
Read the full narrative on Primoris Services (it's free!)
Primoris Services' narrative projects $8.7 billion revenue and $358.2 million earnings by 2028. This requires 7.7% yearly revenue growth and about a $117 million earnings increase from $241.0 million today.
Uncover how Primoris Services' forecasts yield a $152.86 fair value, a 11% upside to its current price.
Exploring Other Perspectives
Before this news, the most optimistic analysts were counting on revenue of about US$8.2 billion and earnings of roughly US$338 million by 2028, which is far more upbeat than consensus and could look either too cautious or too optimistic once you factor in concerns about heavy fossil fuel exposure and how new projects actually shake out.
Explore 5 other fair value estimates on Primoris Services - why the stock might be worth less than half the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Primoris Services research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Primoris Services research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Primoris Services' overall financial health at a glance.
No Opportunity In Primoris Services?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
- AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com